Terms: = Prostate cancer AND ELK4, SAP1, 2005, ENSG00000158711, P28324 AND Treatment
850 results:
1. Critical survival periods in prostate cancer in Sweden explored by conditional survival analysis.
Hemminki K; Zitricky F; Sundquist K; Sundquist J; Försti A; Hemminki A; Hemminki O
Cancer Med; 2024 Apr; 13(7):e7126. PubMed ID: 38545829
[TBL] [Abstract] [Full Text] [Related]
2. Decline in cancer Diagnoses during the 'Zero COVID' Policy in Hong Kong: Indirect Spillover Impact of the COVID-19 Pandemic.
Youn HM; Zhang Y; Liu A; Ng CS; Liang J; Lau GKK; Lee SF; Lok J; Lam CLK; Wan EYF; Quan J
Clin Oncol (R Coll Radiol); 2024 Mar; 36(3):157-164. PubMed ID: 38262779
[TBL] [Abstract] [Full Text] [Related]
3. Fewer systematic prostate core biopsies in clinical stage T1c prostate cancer leads to biochemical recurrence after brachytherapy as monotherapy.
Ozawa Y; Nohara S; Nakamura K; Hattori S; Yagi Y; Nishiyama T; Yorozu A; Monma T; Saito S
Prostate; 2024 Apr; 84(5):502-510. PubMed ID: 38173289
[TBL] [Abstract] [Full Text] [Related]
4. A Literature Review of Racial Disparities in prostate cancer Research.
Vermeille M; Koster KL; Benzaquen D; Champion A; Taussky D; Kaulanjan K; Früh M
Curr Oncol; 2023 Nov; 30(11):9886-9894. PubMed ID: 37999138
[TBL] [Abstract] [Full Text] [Related]
5. Reevaluating age restrictions of spinal metastasis surgery in elderly groups with over 2-year follow-up.
Lenga P; Dao Trong P; Papakonstantinou V; Kiening K; Unterberg AW; Ishak B
Neurosurg Rev; 2023 Nov; 46(1):309. PubMed ID: 37987881
[TBL] [Abstract] [Full Text] [Related]
6. Impact of multimorbidity and polypharmacy on mortality after cancer: a nationwide registry-based cohort study in Denmark 2005-2017.
Thomsen MK; Løppenthin KB; Bidstrup PE; Andersen EW; Dalton S; Petersen LN; Pappot H; Mortensen CE; Christensen MB; Frølich A; Lassen U; Johansen C
Acta Oncol; 2023 Dec; 62(12):1653-1660. PubMed ID: 37874076
[TBL] [Abstract] [Full Text] [Related]
7. Differential Use of Radiotherapy Fractionation Regimens in prostate cancer.
Qureshy SA; Diven MA; Ma X; Marciscano AE; Hu JC; McClure TD; Barbieri C; Nagar H
JAMA Netw Open; 2023 Oct; 6(10):e2337165. PubMed ID: 37815829
[TBL] [Abstract] [Full Text] [Related]
8. Cardiorespiratory fitness and BMI measured in youth and 5-year mortality after site-specific cancer diagnoses in men-A population-based cohort study with register linkage.
Onerup A; Mehlig K; Ekblom-Bak E; Lissner L; Börjesson M; Åberg M
Cancer Med; 2023 Oct; 12(19):20000-20014. PubMed ID: 37732468
[TBL] [Abstract] [Full Text] [Related]
9. Rosiglitazone has a null association with the risk of prostate cancer in type 2 diabetes patients.
Tseng CH
Front Endocrinol (Lausanne); 2023; 14():1185053. PubMed ID: 37560306
[TBL] [Abstract] [Full Text] [Related]
10. Trends in the use of local intervention for metastatic hormone-naïve prostate cancer: A multicenter retrospective study.
Tanaka R; Hatakeyama S; Narita S; Sakurai T; Tanaka T; Miura H; Oishi T; Kawamura S; Hoshi S; Ishidoya S; Mitsuzuka K; Ito A; Tsuchiya N; Habuchi T; Ohyama C
Int J Urol; 2023 Nov; 30(11):969-976. PubMed ID: 37403901
[TBL] [Abstract] [Full Text] [Related]
11. Risks of alcohol and drug use disorders in prostate cancer survivors: a national cohort study.
Crump C; Stattin P; Brooks JD; Sundquist J; Edwards AC; Sieh W; Sundquist K
JNCI Cancer Spectr; 2023 Jul; 7(4):. PubMed ID: 37389442
[TBL] [Abstract] [Full Text] [Related]
12. Does Research from Clinical Trials in Metastatic Hormone-sensitive prostate cancer treatment Translate into Access to treatments for Patients in the "Real World"? A Systematic Review.
Dodkins J; Nossiter J; Cook A; Payne H; Clarke N; van der Meulen J; Aggarwal A
Eur Urol Oncol; 2024 Feb; 7(1):14-24. PubMed ID: 37380578
[TBL] [Abstract] [Full Text] [Related]
13.
Alzoubi A; Al Bashir S; Smairat A; Alrawashdeh A; Haddad H; Kheirallah K
J Med Life; 2023 Apr; 16(4):593-598. PubMed ID: 37305830
[TBL] [Abstract] [Full Text] [Related]
14. Comparing Risk for Second Primary cancers After Intensity-Modulated vs 3-Dimensional Conformal Radiation Therapy for prostate cancer, 2002-2015.
Pithadia KJ; Advani PG; Citrin DE; Bekelman JE; Withrow DR; Berrington de Gonzalez A; Morton LM; Schonfeld SJ
JAMA Oncol; 2023 Aug; 9(8):1119-1123. PubMed ID: 37289449
[TBL] [Abstract] [Full Text] [Related]
15. Testosterone treatment of Men with Unequivocal Hypogonadism Following treatment of Organ-Confined prostate cancer.
Jones RB; Snyder PJ
Endocr Pract; 2023 Sep; 29(9):723-726. PubMed ID: 37236354
[TBL] [Abstract] [Full Text] [Related]
16. Changing nationwide trends away from overtreatment among patients undergoing radical prostatectomy over the past 25 years.
Meissner VH; Glöckler V; Jahnen M; Schiele S; Gschwend JE; Herkommer K
World J Urol; 2023 Jun; 41(6):1497-1502. PubMed ID: 37195312
[TBL] [Abstract] [Full Text] [Related]
17. Long-term Risks of Depression and Suicide Among Men with prostate cancer: A National Cohort Study.
Crump C; Stattin P; Brooks JD; Sundquist J; Bill-Axelson A; Edwards AC; Sundquist K; Sieh W
Eur Urol; 2023 Sep; 84(3):263-272. PubMed ID: 37169640
[TBL] [Abstract] [Full Text] [Related]
18. 15-year biochemical failure, metastasis, salvage therapy, and cancer-specific and overall survival rates in men treated with robotic radical prostatectomy for PSA-screen detected prostate cancer.
Sood A; Grauer R; Diaz-Insua M; Tewari AK; Hemal AK; Shrivastava A; Peabody JO; Jeong W; Abdollah F; Rudzinski JK; Andrews JR; Gorin MA; Bhandari M; Menon M
Prostate Cancer Prostatic Dis; 2023 Dec; 26(4):778-786. PubMed ID: 37142635
[TBL] [Abstract] [Full Text] [Related]
19. Radiotherapy after radical prostatectomy for prostate cancer: clinical outcomes and factors influencing biochemical recurrence.
Fukuda I; Aoki M; Kimura T; Ikeda K
Ir J Med Sci; 2023 Dec; 192(6):2663-2671. PubMed ID: 37097540
[TBL] [Abstract] [Full Text] [Related]
20. Low hemoglobin and PSA kinetics are prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients.
Hakozaki Y; Yamada Y; Takeshima Y; Taguchi S; Kawai T; Nakamura M; Iwaki T; Teshima T; Kinoshita Y; Akiyama Y; Sato Y; Yamada D; Suzuki M; Kume H
Sci Rep; 2023 Feb; 13(1):2672. PubMed ID: 36792713
[TBL] [Abstract] [Full Text] [Related]
[Next]
